CONCLUSIONS: Cabazitaxel, gemcitabine and cisplatin appears to be a well-tolerated intravesical salvage chemotherapy regimen for the treatment of BCG-refractory non-muscle invasive bladder cancer.
INTRODUCTION AND OBJECTIVES: Non muscle invasive bladder cancer is a recurrent and progressive disease; currently we are unable to forecast recurrence in the individual patient. Recently we developed a mathematical model that found NLR as a good prognostic tool. The model was tested retrospectively in an additional study and found accurate too. The aim of the current study is to assess its accuracy to forecast recurrence prospectively in patients with NMIBC METHODS: All patients admitted to bladder tumor resection (TURBT) and agreed to participate in the study had blood drawn for blood count 24 hours prior to surgery. Patients with non-muscle invasive tumor were recruited and prospectively followed. Patients had urine cytology and cystoscopy every 3 months for 2 years following resection. Time to recurrence and recurrence free of tumor were recorded. Statistical analysis was done with X2 test for categorical parameters and T test for serial parameters. Logistic regression was performed to forecast prognosis.
RESULTS: 123 patients were recruited, mean age was 71 years, all patients had at least 1 year follow up. Twenty nine patients (23.6%) experienced biopsy proven tumor recurrence. The mean time for recurrence was 7.38 months.Neutrophil to Lymphocyte rate > 2 showed direct statistically significant correlation with tumor recurrence (p¼0.038), tumor stage showed the same correlation (p¼0.048). The specificity of our recurrence forecasting model was 96.8%. EORTC score did not demonstrate significance between the recurrent and nonrecurrent groups.
CONCLUSIONS: Our mathematical model that found NLR as a prognostic tool in patients with NMIBC was tested for the first time prospectively. The model demonstrated its ability to forecast recurrence more accurately then tumor stage grade and EORT score in the individual patient with NMIBC.The main limitation of this work is the relatively low number of patients.
INTRODUCTION AND OBJECTIVES: Cytokeratin 20 (CK20) and Insulin-like growth factor 2 (IGF2) were previously proposed to be elevated in patients with bladder cancer (BCa). A two cohort design validation study was used to assess the relevance for BCa detection of both markers in urine samples. The results were compared to voided urine cytology (VUC).
METHODS: RNA isolation was carried out using 5 ml spontaneous urine samples of 196 and 97* histologically positive BCa patients for the test and validation* cohort, respectively. Additionally patients with benign urological diseases, nephrolithiasis and unconfirmed BCa suspicion as well as healthy control subjects were included for a total of 103/50* control subjects in the test and validation* cohort. Urinary mRNA levels were determined by qPCR and the results were normalized as molecule ratio to RPLP0. Receiver operating characteristic curves and corresponding AUC values were used to evaluate the diagnostic performance of both markers. Optimal cut-off values were determined by Youden Index.
RESULTS: Urinary mRNA levels were significantly elevated 3.4/11*-fold for CK20 and 188/64*-fold for IGF2 in BCa patients compared to controls in the test and validation* cohort, respectively. IGF2 performed slightly better with an AUC of 0.83 for both cohorts compared to CK20 with an AUC of 0.78 and 0.82* for the test and validation* cohort, respectively. Combined analysis of IGF2 and CK20 with at least one positive marker resulted in a sensitivity (0.78/0.90*) and specificity (0.88/0.84*) similar to that of VUC. The sensitivity of VUC in combination with IGF2 and CK20 was considerably increased (0.95/ 0.93*) while specificity was slightly reduced (0.72/0.84*) compared to VUC alone in the test and validation* cohort.
CONCLUSIONS: Expressions of IGF2 and CK20 correlated significantly with BCa with a diagnostic performance similar to VUC. Combined analysis of voided urine cytology together with expression levels of CK20 and IGF2 clearly enhances overall test performance. Therefore, its relevance for BCa diagnosis should be evaluated in a larger cohort.
INTRODUCTION AND OBJECTIVES: Radical cystectomy (RC) remains underutilized in patients with non-muscle invasive bladder cancer (NMIBC), particularly elderly patients, despite data demonstrating inferior survival for patients with NMIBC who experience disease progression. We evaluated the association of age with perioperative and oncologic outcomes after RC for NMIBC.
METHODS: Multi-institutional review of patients with NMIBC managed with RC between 2000-2013. Patients were stratified by age: <70 versus 70. Associations of age with receipt of perioperative blood transfusion (PBT), prolonged operative time (75th%; pORT) and length of stay (75th%; pLOS), pathology at RC, and 30/90 day complications were assessed using multivariable logistic regression. Recurrence-free (RFS), cancer-specific (CSS), and overall survival (OS) were evaluated using the Kaplan-Meier method, multivariable Cox proportional hazards regression models, and competing risks models.
RESULTS: A total of 489 patients were identified, of whom 263 (55.8%) were <70 and 226 (46.2%) were 70. On multivariable analysis, age 70 was not significantly associated with patients' risk of receipt of a PBT, pORT, pathologic stage pT2-4 or pN+, 30 day or 90 day grade III+ complications (all p>0.05). pLOS was more likely in older patients (OR 1.77; 95%CI 1.09-2.85; p¼0.02). Estimated 5-yr RFS, CSS, and OS in patients <70 versus 70 was 70% vs 62% (p¼0.14), 84% vs 77% (p¼0.06), and 74% vs 54% (p<0.01). On multivariable Cox regression analyses, age 70 was not independently associated with RFS (HR 1.10; 95% CI 0.79-1.52; p¼0.57) or CSS (HR 1.22; 95% CI 0.82-1.82; p¼0.32), but remained associated with decreased OS (HR 1.91; 95% CI 1.50-2.45; p<0.01). Moreover, among all patients and as stratified by age, pathologic upstaging was associated with worse RFS, CSS, and OS on both multivariable Cox proportional hazards regression and in competing risk (of non-cancer death) models (Table) .
CONCLUSIONS: Older patients with NMIBC had similar risks of pathologic upstaging at RC, and patients upstaged at surgery had inferior cancer outcomes across age strata. Meanwhile, advanced age was not associated with increased risks of PBT, pORT, or perioperative complications. These data support the use of RC for select older patients with high-risk NMIBC.
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MP15-17 BEYOND SUPPLEMENTATION: THE ROLE OF VITAMIN D IN NON-MUSCLE INVASIVE BLADDER CANCER
Ziting Wang*, Yew Koon Lim, Ratha Mahendran, Esuvaranathan Kesavan, Edmund Chiong, Singapore, Singapore INTRODUCTION AND OBJECTIVES: The Vitamin D Receptor (VDR) gene has been found to regulate the expression of cathelicidin, an antimicrobial peptide which represent a significant portion of the body's immune response against mycobacterium tuberculosis. VDR is also associated with macrophage phagocytosis, which is a key driver of the cell-mediated immunological response stimulated by BacillusCalmette Guerin (BCG). Various VDR single nucleotide polymorphisms (SNP) have been found to be associated with increased susceptibility to pulmonary tuberculosis. Hence, we hypothesize that this group of patients may similarly be unable to mount an immune response during the administration of intravesical BCG. In this study, we evaluated the predictive role of 3 VDR SNPs in the context of Asian patients with non-muscle invasive bladder cancer (NMIBC) recurrence and BCG immunotherapy outcome.
METHODS: Peripheral blood DNA was prospectively obtained from 140 evaluable EORTC intermediate to high risk NMIBC patients, who underwent post-transurethral resection intravesical regimes of BCG or BCG with interferon alpha. 3 VDR SNPs commonly implicated in susceptibility to tuberculosis infections were evaluated using high resolution melt (HRM) analysis. Results were confirm with sequence analysis. Kaplan-Meier together with Log-Rank test and Cox regression methods were used to analyze the data. RESULTS: Genotype frequencies were similar between the NMIBC patients and controls in accordance to the Hardy Weinberg equilibrium. Mean follow-up time was 91.9 months. Overall mean time to recurrence and progression was 25.8 months and 47.0 months respectively. Kaplan-Meier analysis indicate that individuals carrying the VDR genotype rs1544410 A/G were significantly associated with lower recurrence-free survival rates after BCG therapy (p¼0.007). The VDR rs1544410 "A" allele frequency was found to be higher in patients with bladder cancer recurrences (p¼0.01). 100.0% of patients with the VDR genotype rs731236 C/C had carcinoma in situ of the bladder, compared to 20.5% of the patients with the genotype T/T and 12.5% of the patients with the genotype T/C (?2 (2)¼ 8.31, p¼0.016). No association of VDR genotypes with progression-free survival was found.
CONCLUSIONS: Our findings suggest that polymorphisms in the VDR gene correlate with response to BCG therapy in NMIBC patients and further work should be performed to evaluate their utility as predictive markers of response to BCG immunotherapy. 
INTRODUCTION AND OBJECTIVES:
The Combat BRS system is a novel hyperthermia delivering device which allows temperature controlled delivery and re-circulation of HM via a urethral catheter using an external heat source. HIVEC I and II are two randomized control trials to determine if HM is superior to MMC alone in intermediate risk non-muscle invasive bladder cancer (NMIBC). We report safety and tolerability outcomes comparing the two treatment arms.
METHODS: HIVEC I and II are multi-centre, open-labeled randomized controlled trials recruiting patients from 25 Spanish and UK centers. The HIVEC I randomizes patients to either MMC, HM for 30 mins and HM for 60 mins (HM 60). Patients receive 4 once weekly treatments followed by 3 one monthly treatments. HIVEC II randomizes patients to MMC or HM 60 where both treatment arms receive 6 weekly treatments. Both trials use 40 mg MMC diluted in either 50 ml (HIVEC I) or 40 ml (HIVEC II) of sterile water. We compared all HIVEC I and II patients who were randomized to MMC (n¼154) or HM 60 (n¼153). HM was delivered by heating MMC to 43 C. Adverse events (AE) were reviewed by the independent data monitoring committee. HIVEC I and II were registered with EudraCT (2013-002628-18) and ISRCTN (23639415) respectively. RESULTS: 307 patients were included for analysis. 88.9% and 94.8% of HM and MMC patients respectively completed inductive therapy. Reasons for stopping therapy in 17 HM patients include: MMC allergy (n¼ 11), urinary symptoms (n¼2), pain (n¼1), haematuria (n¼1), pneumonia (n¼1) and in 8 MMC patients include: MMC allergy (n¼7) and angina (n¼1). AE which led to early termination of treatment were Grade II. There was no significant difference in patients with AE between HM (n¼78, 51%) and MMC (n¼66, 42.9%) (p¼0.154). Most AE were Grade ¼II (HM: 97.7%, MMC: 98.5%). There was no Grade >III related AE. There was no difference in pain (HM: 13.1% vs MMC: 8.4, p¼0.190) , dysuria (HM: 5.2% vs MMC: 6.5%, p¼0.617), urgency (HM: 11.8% vs MMC: 3.9%, p¼0.067), incontinence (HM: 3.3% vs MMC: 0.6%, p¼0.097) and rash/ allergic reaction (HM: 7.8% vs MMC: 5.2%, p¼0.327). HM treated patients were significantly more likely to develop urinary frequency (HM: 15.0% vs MMC: 5.8%, p¼0.008), haematuria (HM: 11.8% vs MMC: 3.9%, p¼0.010) and bladder spasm (HM: 6.5% vs MMC: 0.6%, p¼0.006).
CONCLUSIONS: HM delivered using the Combat BRS system is safe and well tolerated. The majority of AE in the HM arm were low grade with urinary frequency and haematuria more common in HM in comparison to MMC treated patients. HM represents a safe and well tolerated intravesical treatment for NMIBC.
